Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.
Risk and Volatility
Brainstorm Cell Therapeutics has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, Agenus has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.
Valuation and Earnings
This table compares Brainstorm Cell Therapeutics and Agenus”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Brainstorm Cell Therapeutics | N/A | N/A | -$17.19 million | ($4.80) | -0.36 |
| Agenus | $156.31 million | 0.52 | -$245.76 million | ($11.24) | -0.31 |
Profitability
This table compares Brainstorm Cell Therapeutics and Agenus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Brainstorm Cell Therapeutics | N/A | N/A | -528.56% |
| Agenus | -145.89% | N/A | -85.68% |
Analyst Ratings
This is a summary of recent ratings and target prices for Brainstorm Cell Therapeutics and Agenus, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Brainstorm Cell Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Agenus | 0 | 5 | 1 | 0 | 2.17 |
Brainstorm Cell Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 1,624.14%. Agenus has a consensus price target of $10.00, indicating a potential upside of 186.53%. Given Brainstorm Cell Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Agenus.
Institutional & Insider Ownership
14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 6.7% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 4.6% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Brainstorm Cell Therapeutics beats Agenus on 6 of the 11 factors compared between the two stocks.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
About Agenus
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
